Replimune Investors Face October Deadline in Securities Fraud Lawsuit

The complaint alleges that Replimune misled the market by failing to disclose critical FDA concerns regarding the design of its Biologics License Application. Specifically, the suit claims the company submitted data from an unplanned analysis of the RP1-104 study that included only 10% of the planned enrollment, a move that reportedly signaled a high likelihood of regulatory rejection. These omissions allegedly rendered the company’s public statements throughout the class period materially false.

Shareholders who incurred financial losses during this window may contact Brian Schall or David Schwartz at the Los Angeles-based firm to discuss their legal standing. While the class has not yet been certified, investors retain the right to participate in potential recoveries or remain absent members of the class. The firm notes that no formal appointment is required to benefit from any final judgment or settlement reached in the case.